EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A retrospective analysis to evaluate if KIR B haplotype donors associate with a reduced risk of relapse in patients with haematological malignancies following haploidentical transplantation at the Blood and Bone Marrow Transplant Unit at Hammersmith Hospital ICHNHST

Christopher Paul Byrnes, Andrew Hastings, Ira Lacej, Renuka Palanicawandar, Eduardo Olavarria, Arthi Anand

HLA · 2024

DOI: 10.1111/tan.15214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HLA, 2024. Verfasst von Christopher Paul Byrnes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Histocompatibility and Immunogenetics laboratory, Infection & Immunity sciences, North West London Pathology, Imperial College Healthcare NHS Trust, …. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Hematologic Neoplasms, Graft vs Host Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National School of Healthcare Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapse is a major cause of treatment failure in haploidentical haematopoietic progenitor cell transplant (HPCT) with PTCy. Natural killer cells suppress graft versus host disease and mediate the graft versus leukaemia effect, driven by killer cell immunoglobulin‐like receptors (KIRs). Emerging research suggests that donor KIR genotype may influence graft outcome in haploidentical transplants with varying impacts between patient cohorts. This study investigates whether donors with greater KIR B motifs associate with outcomes such as greater relapse‐free survival (RFS), overall survival (OS), nonrelapse mortality (NRM), acute graft versus host disease (GvHD) and infection. The study cohort included 98 haploidentical donor–recipient (D/R) pairs (myeloablative n = 37, RIC n = 61) with various haematological malignancies, receiving primary T‐cell replete haploidentical HSCT with PTCγ. Following KIR SSO genotyping, donors are categorised into neutral ( n = 63) or better and best ( n = 35), based on KIR B motif content. Kaplan–Meier and Cox regression survival functions are performed to investigate associations with outcomes. Our results show that the better and best category has significantly poorer RFS ( p = 0.013; hazard ratio [HR] 3.16, 95% CI 1.21–8.24: p = 0.018). The greater risk of relapse associated with poorer OS ( p = 0.011; HR 2.24, 95% CI 1.18–4.24: p = 0.01) in the better and best category. The competing KIR receptor‐ligand and missing licensing proof models failed to predict transplant outcomes. Here, we show neutral donors associate with favourable outcomes in T‐cell replete haplo‐HPCT with PTCγ after categorisation using the KIR B content model, due to the increased risk of relapse associated with the use of better and best donors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationHematologic NeoplasmsGraft vs Host DiseaseHumansRetrospective StudiesHaplotypesTransplantation, HaploidenticalAllelesNeoplasm Recurrence, LocalReceptors, KIRChronic Disease

Stichwörter der Autor:innen

HLAhaematopoietic progenitor cell transplanthaploidentical transplantkiller cell immunoglobulin-like receptorsnatural killer cells

Substanzen

Receptors, KIR

Autor:innen und Institutionen

  • Histocompatibility and Immunogenetics laboratory, Infection & Immunity sciences, North West London Pathology, Imperial College Healthcare NHS Trust, London, UK.
  • School of Medical Sciences, University of Manchester, Manchester, UK.
  • Imperial College Healthcare NHS Trust, London, UK.
  • Department of Haematology, Imperial College Healthcare NHS Trust, London, UK.

Förderung

  • National School of Healthcare Science

Zitieren

APA

Byrnes, C. P., Hastings, A., Lacej, I., Palanicawandar, R., Olavarria, E., & Anand, A. (2024). A retrospective analysis to evaluate if KIR B haplotype donors associate with a reduced risk of relapse in patients with haematological malignancies following haploidentical transplantation at the Blood and Bone Marrow Transplant Unit at Hammersmith Hospital ICHNHST. HLA. https://doi.org/10.1111/tan.15214

Vancouver

Byrnes CP, Hastings A, Lacej I, Palanicawandar R, Olavarria E, Anand A. A retrospective analysis to evaluate if KIR B haplotype donors associate with a reduced risk of relapse in patients with haematological malignancies following haploidentical transplantation at the Blood and Bone Marrow Transplant Unit at Hammersmith Hospital ICHNHST. HLA. 2024. doi:10.1111/tan.15214

BibTeX
@article{Byrnes2024,
  author = {Byrnes, Christopher Paul and Hastings, Andrew and Lacej, Ira and Palanicawandar, Renuka and Olavarria, Eduardo and Anand, Arthi},
  title = {A retrospective analysis to evaluate if KIR B haplotype donors associate with a reduced risk of relapse in patients with haematological malignancies following haploidentical transplantation at the Blood and Bone Marrow Transplant Unit at Hammersmith Hospital ICHNHST},
  journal = {HLA},
  year = {2024},
  doi = {10.1111/tan.15214}
}
Kostenlos starten →